Will a syringe and a vial deliver the same obesity drug dose?

NCT ID NCT07768813

NEW Not yet recruiting Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial asks whether two different ways of giving survodutide—a pre-filled syringe and a vial—deliver the same amount of drug into the body. It involves healthy adults or those who are overweight or obese, aged 18 to 55. Each participant receives a single dose of both forms at different times to compare how the body absorbs them. The goal is to see if the two versions are interchangeable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: survodutide (BI 456906) in two formulations: a pre-filled syringe and a vial
What this could lead to: If the two forms are equivalent, it could offer more flexible options for delivering survodutide, a potential treatment for obesity and related conditions.
What could go wrong: This is an early-phase trial focused on drug absorption, not on weight loss or safety outcomes. Results may not reflect real-world effectiveness, and the drug may still fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OBESITY

Contacts and locations

Locations

hVIVO Mannheim

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.